Literature DB >> 17852882

Gastrointestinal stromal tumors of the rectum: Clinical, pathologic, immunohistochemical characteristics and prognostic analysis.

Chen Dong1, Cui Jun-Hui, Yang Xiao-Jun, Kong Mei, Wang Bo, Jiang Chen-Fe, Yang Wei-Li.   

Abstract

OBJECTIVE: To describe the clinical, pathological and immunohistochemical characteristics of rectal gastrointestinal stromal tumors (GISTs) and to correlate them with clinical outcomes.
MATERIAL AND METHODS: A retrospective review of 29 patients with surgically treated rectal GISTs during the period from 1997 to 2005 was undertaken. The NIH (National Institute of Health Consensus) criteria were applied.
RESULTS: All the rectal GISTs in our series originated in the lower half of the rectum and patients underwent primary surgery for complete resections; High-risk, intermediate-risk, low-risk and very low-risk GISTs were found in 11, 6, 5 and 7 patients, respectively. Necrosis, adjacent (mucosal or serosa) invasion and marked pleomorphisms were found in 10, 7 and 20 patients, respectively. Positive expression of CD117, CD34, SMA and S-100 was found in 28, 28, 7 and 3 patients, respectively. Twelve patients had recurrence or metastasis within the median disease-free survival time of 41 months. Among the patients who underwent local resections, the recurrence rate for low-risk and very low-risk GISTs was only 1/10; for intermediate-risk and high-risk GISTs, the recurrence rate after local resections was 3/4, which was higher than the recurrence and metastasis rate of 8/13 after laparotomy. Of the 12 patients with adverse outcomes, 4 patients underwent secondary complete resections; however, all 4 patients had further recurrences. On univariate analysis, risk classification (p = 0.0002), necrosis (p = 0.0205), adjacent invasion (p = 0.0090) and marked pleomorphism (p = 0.0480) were significant predictors of disease-free survival. In the Cox regression model, only the risk classification (p = 0.012) was found to be an independent factor.
CONCLUSION: We found that rectal GISTs arise predominantly in the lower half of the rectum and have high CD117 and CD34 expression. Local resection may be a good choice for very-low-risk and low-risk GISTs, but aggressive surgery may be more beneficial for high-risk and intermediate-risk GISTs. For patients with disease recurrence, the results of secondary surgery were poor. Only the NIH risk classification proved to be an independent prognostic factor for rectal GISTs, whereas the proof for other factors was insufficient.

Entities:  

Mesh:

Year:  2007        PMID: 17852882     DOI: 10.1080/00365520701376507

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  9 in total

1.  Anorectal gastrointestinal stromal tumors: a retrospective multicenter analysis of 15 cases emphasizing their high local recurrence rate and the need for standardized therapeutic approach.

Authors:  Abbas Agaimy; Nikolaos Vassos; Bruno Märkl; Norbert Meidenbauer; Jens Köhler; Johann Spatz; Werner Hohenberger; Florian Haller; Roland S Croner; Regine Schneider-Stock; Klaus Matzel
Journal:  Int J Colorectal Dis       Date:  2013-02-13       Impact factor: 2.571

2.  The efficacy of adjuvant imatinib therapy in improving the prognosis of patients with colorectal gastrointestinal stromal tumours.

Authors:  Y Li; X Meng
Journal:  Ann R Coll Surg Engl       Date:  2015-04       Impact factor: 1.891

3.  The Impact of Imatinib on Survival and Treatment Trends for Small Bowel and Colorectal Gastrointestinal Stromal Tumors.

Authors:  Hamda Almaazmi; Miloslawa Stem; Brian D Lo; James P Taylor; Sandy H Fang; Bashar Safar; Jonathan E Efron; Chady Atallah
Journal:  J Gastrointest Surg       Date:  2019-08-06       Impact factor: 3.452

4.  Gastrointestinal tumors of the colon and rectum.

Authors:  Dimitra G Theodoropoulos
Journal:  Clin Colon Rectal Surg       Date:  2011-09

5.  Localized gastrointestinal stromal tumor of the rectum: An uncommon primary site with prominent disease and treatment-related morbidities.

Authors:  Mohamad Farid; Marcus Jin Fu Lee; Min Hoe Chew; Whee Sze Ong; Alisa Noor Hidayah Sairi; Kian Fong Foo; Su Pin Choo; Wen Hsin Koo; Simon Ong; Poh Koon Koh; Richard Quek
Journal:  Mol Clin Oncol       Date:  2012-09-19

6.  [Rectal stromal tumor: report of a case].

Authors:  Haitham Rejab; Wala Ben Kridis; Hazem Ben Ameur; Jihene Feki; Mounir Frikha; Mohamed Issam Beyrouti
Journal:  Pan Afr Med J       Date:  2014-02-18

7.  Clinicopathological features and prognosis of small gastrointestinal stromal tumors outside the stomach.

Authors:  Yong-Peng Wang; Y I Li; Chun Song
Journal:  Oncol Lett       Date:  2015-08-25       Impact factor: 2.967

8.  Prognostic value of tumor necrosis in gastrointestinal stromal tumor: A meta-analysis.

Authors:  Mengshi Yi; Lin Xia; Yan Zhou; Xiaoting Wu; Wen Zhuang; Yi Chen; Rui Zhao; Qianyi Wan; Liang Du; Yong Zhou
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

9.  Transanal versus nontransanal surgery for the treatment of primary rectal gastrointestinal stromal tumors: a 10-year experience in a high-volume center.

Authors:  Zifeng Yang; Wentai Guo; Rongkang Huang; Minhui Hu; Huaiming Wang; Hui Wang
Journal:  Ann Transl Med       Date:  2020-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.